Last reviewed · How we verify

Redemplo — Competitive Intelligence Brief

Redemplo (PLOZASIRAN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: APOC-III-directed RNA Interaction [EPC]. Area: Metabolic.

marketed APOC-III-directed RNA Interaction [EPC] apoC-III mRNA Metabolic Oligonucleotide Live · refreshed every 30 min

Target snapshot

Redemplo (PLOZASIRAN) — Arrowhead. Plozasiran reduces hepatic and serum apoC-III protein by degrading apoC-III mRNA via RNA interference, leading to increased clearance of serum triglycerides.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Redemplo TARGET PLOZASIRAN Arrowhead marketed APOC-III-directed RNA Interaction [EPC] apoC-III mRNA 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (APOC-III-directed RNA Interaction [EPC] class)

  1. Arrowhead · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Redemplo — Competitive Intelligence Brief. https://druglandscape.com/ci/plozasiran. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: